Warning: getimagesize(/home/aristo/public_html/labmedica/images/stories/articles/article_images/_BR/20130602 - GMS188a.gif articles/article_images/_BR/20130602 - GMS188b.gif): failed to open stream: No such file or directory in /home/www/medsites/linkxpress/includes/Helper/JSONLD.php on line 175
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Intranasal Antibody Gene Transfer in Mice and Ferrets Protects Against Influenza Infection

By LabMedica International staff writers
Posted on 13 Jun 2013
Transmission of the influenza virus was blocked in animal models by a gene therapy technique that introduced a neutralizing antibody gene directly into the cells lining the nose and respiratory system.

Investigators at the University of Pennsylvania (Philadelphia, USA) worked with mouse and ferret influenza models. More...
To protect these animals against influenza A infection the investigators used a modified adeno-associated virus (AAV) vector to deliver the gene that encodes the broadly neutralizing monoclonal anti-influenza antibody FI6 directly into the nasopharyngeal mucosa of the mice and ferrets.

Test animals were exposed to lethal quantities of three strains of influenza serotype H5N1 and two strains of serotype H1N1, all of which were associated with historic human pandemics (including the H1N1 1918 "Spanish flu" pandemic).

The investigators reported in the May 29, 2013, online edition of the journal Science Translational Medicine that intranasal delivery of the FI6 gene afforded complete protection against influenza infection in both the mouse and ferret model systems.

“The experiments described in our paper provide critical proof-of-concept in animals about a technology platform that can be deployed in the setting of virtually any pandemic or biological attack for which a neutralizing antibody exists or can be easily isolated,” said senior author Dr. James. M. Wilson, professor of pathology and laboratory medicine at the University of Pennsylvania. “Further development of this approach for pandemic flu has taken on more urgency in light of the spreading infection in China of the lethal bird strain of H7N9 virus in humans.”


Related Links:
University of Pennsylvania



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.